DCSIMG
LOVENOX®- In-Hospital DVT Blood Clot Risk
KNOW LOVENOX®

In-Hospital DVT Risk

If you are receiving epidural or spinal anesthesia or undergoing spinal puncture, and taking LOVENOX® (enoxaparin sodium injection), you may be at increased risk of developing a blood clot in or around the spine, which can result in long-term paralysis. Your risk may be further increased if you:

  • Take nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants, such as aspirin or blood thinners
  • Have an indwelling epidural catheter
  • Have a history of spinal trauma, or repeated spinal anesthesia or punctures
  • Have a history of spinal deformities or spinal surgery

It is important to contact your doctor immediately if you experience symptoms such as tingling, numbness (especially in the lower limbs), and muscular weakness.

If you are being hospitalized for abdominal surgery, hip- or knee-replacement surgery, or have extended periods of immobility as a result of acute illness, you are at increased risk of DVT blood clots. LOVENOX® can help reduce this risk.

The following conditions may also increase risk:

  • Congestive heart failure —This condition may triple the risk of developing DVT blood clots, depending on the severity.
  • Flare-ups of COPD —DVT blood clots that move to the lung may cause a potentially fatal condition known as pulmonary embolism (PE).
  • Acute infection
  • Certain cancers—Complications from DVT blood clots are the second leading cause of death among certain cancer patients. For people receiving chemotherapy, the risk of a DVT blood clot can be higher than in people free from cancer.
  • Surgery—Damage may occur to blood vessels during abdominal surgery, as well as hip- or knee-replacement surgery, which can initiate the development of DVT blood clots in some patients.

Other DVT risk factors*

  • Age over 40 years
  • Restricted mobility
  • Intensive care admission
  • Inflammatory bowel disease
  • Prior history of a DVT blood clot
  • Varicose veins
  • Smoking
  • Obesity

*This is a partial listing of risk factors. Learn more by speaking to the hospital-based doctors and nurse specialists managing your care, and ask them if LOVENOX® is right for you.

LOVENOX® can help reduce the risk of developing DVT blood clots, which may lead to PE, in patients undergoing abdominal surgery, hip- or knee-replacement surgery, or in acutely ill medical patients with severely restricted mobility.


Important Safety Information

If you are receiving epidural or spinal anesthesia or undergoing spinal puncture, and taking LOVENOX® (enoxaparin sodium injection), you may be at increased risk of developing a blood clot in or around the spine, which can result in long-term paralysis. Your risk may be further increased if you:

  • Take nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants, such as aspirin or blood thinners
  • Have an indwelling epidural catheter
  • Have a history of spinal trauma, or repeated spinal anesthesia or punctures
  • Have a history of spinal deformities or spinal surgery

It is important to contact your doctor immediately if you experience symptoms such as tingling, numbness (especially in the lower limbs), and muscular weakness.

LOVENOX® should not be used in patients who are actively bleeding or who have a low count of blood cells called platelets, which aid in clotting. This is a condition called "thrombocytopenia." LOVENOX® also should not be used in patients who are allergic or sensitive to LOVENOX® or enoxaparin, heparin, or pork products.

LOVENOX® must be used with care in patients who have any of the following: problems with clotting, uncontrolled high blood pressure, a recent ulcer, impaired vision due to diabetes, kidney problems, and excessive bleeding. Pregnant women with mechanical prosthetic (artificial) heart valves may be at higher risk for blood clots. These patients who are treated with LOVENOX® must be carefully monitored by their doctor.

Some patients on LOVENOX® can experience drops in their platelet counts, a condition called "thrombocytopenia." Also, a serious but rare condition called "heparin-induced thrombocytopenia" can occur with LOVENOX®. If you have had this condition, you must notify your healthcare professional.

LOVENOX® alters the blood’s ability to clot. Excessive bleeding (hemorrhage), leading to death, has occurred with LOVENOX®. Bleeding can occur at any site with LOVENOX® use. The use of aspirin and other NSAIDs may enhance the risk of excessive bleeding. Be sure to tell all your doctors and dentist about all of the medications you are taking, including those you are taking without a prescription, such as aspirin or other NSAIDs. Also be sure to tell your doctor or dentist you are taking LOVENOX® before any surgery is scheduled and before any new drug is taken.

All patients should be carefully monitored by their doctor while taking LOVENOX®. Your doctor is likely to obtain blood tests that measure your blood count and check for signs of hidden bleeding while you are on LOVENOX®.

You should call your doctor immediately if you notice any of the following: unusual bleeding or bleeding that lasts a long time, unusual bruising, signs of thrombocytopenia (such as a rash or dark spots under the skin), tingling or numbness (especially in the lower limbs), and muscular weakness.

The most common side effects from the use of LOVENOX® are mild pain, irritation, bruising, or redness of the skin at the site of injection. Other common side effects include bleeding, anemia, diarrhea, and nausea.

Do not stop taking LOVENOX® without first talking to the doctor who prescribed it for you.

For specific questions about your health, you should always consult your doctor or a qualified healthcare professional who is responsible for your care.

For more information, call sanofi-aventis U.S. Medical Information Services at 1-800-633-1610.

Please see Full Prescribing Information, including boxed WARNING, for additional important information.

Indications

LOVENOX® is indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism:
  • In patients undergoing abdominal surgery who are at risk for thromboembolic complications
  • In patients undergoing hip-replacement surgery, during and following hospitalization
  • In patients undergoing knee-replacement surgery
  • In medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness

LOVENOX® injection is indicated for:
  • The inpatient treatment of acute deep vein thrombosis, with or without pulmonary embolism, when administered in conjunction with warfarin sodium
  • The outpatient treatment of acute deep vein thrombosis, without pulmonary embolism, when administered in conjunction with warfarin sodium

Prescription LOVENOX® is available in pharmacies.

Click here for information on Sharps Medical Waste Disposal.